Abstract
Background
Bariatric surgery is indicated for major weight loss and for the control of associated comorbidities, particularly type 2 diabetes. Remission prediction scores have been proposed for this end, such as: DiaRem, Ad-DiaRem, ABCD, and DiaBetter. Nevertheless, they have not been evaluated all together in a specific population.
Methods
Retrospective study with Mexican patients submitted to gastric bypass with at least 12 months follow-up. All patients had BMI > 30 kg/m2 and type 2 diabetes. The primary objective was to evaluate the remission prediction performance of scores. A baseline analysis (anthropometric, biochemical, and metabolic) and remission rates were obtained. Remission scores and cut-off values were assigned based on original descriptions. A ROC analysis was performed for sensibility and specificity.
Results
A total of 95 patients were included. Mean age 44 years, 85.6% female with mean BMI of 44.1 kg/m2, and mean HbA1C of 7.2%. At 12 months, complete remission was obtained in 76.8%. ROC curves were plotted showing that DiaRem had 75.3% sensitivity and 68.2% specificity (AUC 0.723 p = 0.001), Ad-DiaRem had 84.9% and 50% (AUC 0.702 p = 0.002), ABCD had 57.5% and 77.3% (AUC 0.0.690 p = 0.002), and DiaBetter had 72.6% and 77.3% (AUC 0.748 p < 0.001).
Conclusion
In Mexican patients with obesity and type 2 Diabetes, submitted to gastric bypass, remission prediction could be assessed with any current model showing satisfactory sensibility and specificity. Among such models, DiaBetter obtained the best statistical performance in our population. Type 2 diabetes remission rate at 1 year is similar to any other race or ethnicity.
Similar content being viewed by others
References
Leitner DR, Frühbeck G, Yumuk V, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies - EASO can lead the way. Obes Facts. 2017;10:483–92. https://doi.org/10.1159/000480525.
Mandviwala T, Khalid U, Deswal A. Obesity and cardiovascular disease: a risk factor or a risk marker? Curr Atheroscler Rep. 2016;18 https://doi.org/10.1007/s11883-016-0575-4.
Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2004;110:2952–67. https://doi.org/10.1161/01.CIR.0000145546.97738.1E.
Verma S, Hussain ME. Obesity and diabetes: an update. Diabetes Metab Syndr Clin Res Rev. 2017;11:73–9. https://doi.org/10.1016/j.dsx.2016.06.017.
Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. Nat Rev Gastroenterol Hepatol. 2017;14:160–9. https://doi.org/10.1038/nrgastro.2016.170.
Bray GA, Frühbeck G, Ryan DH, et al. Management of obesity. Lancet. 2016;387:1947–56. https://doi.org/10.1016/S0140-6736(16)00271-3.
Shah A, Laferrère B. Diabetes after bariatric surgery. Can J Diabetes. 2017;41:401–6. https://doi.org/10.1016/j.jcjd.2016.12.009.
Still CD, Wood GC, Benotti P, et al. A probability score for preoperative prediction of type 2 diabetes remission following RYGB surgery. Lancet Diabetes Endocrinol. 2014;2:38–45. https://doi.org/10.1016/S2213-8587(13)70070-6.A.
Aron-Wisnewsky J, Sokolovska N, Liu Y, et al. The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass. Diabetologia. 2017;60:1892–902. https://doi.org/10.1007/s00125-017-4371-7.
Lee WJ, Hur KY, Lakadawala M, et al. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis. 2013;9:379–84. https://doi.org/10.1016/j.soard.2012.07.015.
Pucci A, Tymoszuk U, Cheung WH, et al. Type 2 diabetes remission 2 years post Roux-en-Y gastric bypass and sleeve gastrectomy: the role of the weight loss and comparison of DiaRem and DiaBetter scores. Diabet Med. 2018;35:360–7. https://doi.org/10.1111/dme.13532.
Zhang R, Borisenko O, Telegina I, et al. Systematic review of risk prediction models for diabetes after bariatric surgery. Br J Surg. 2016;103:1420–7. https://doi.org/10.1002/bjs.10255.
Alegre-Díaz J, Herrington W, López-Cervantes M, et al. Diabetes and cause-specific mortality in Mexico City. N Engl J Med. 2016;375:1961–71. https://doi.org/10.1056/NEJMoa1605368.
Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133–5. https://doi.org/10.2337/dc09-9036.
Zerrweck-Lopez C. Origen del “bypass gastrico simplificado.” Cir y Cir (English Ed 2015;83:87–8. https://doi.org/10.1016/j.circir.2015.04.030.
Espinosa O, Pineda O, Maydón HG, et al. Type 2 diabetes mellitus outcomes after laparoscopic gastric bypass in patients with BMI <35 kg/m 2 using strict remission criteria: early outcomes of a prospective study among Mexicans. Surg Endosc. 2018;32:1353–9. https://doi.org/10.1007/s00464-017-5815-3.
Aminian A, Brethauer SA, Andalib A, et al. Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann Surg. 2017;266:650–7. https://doi.org/10.1097/SLA.0000000000002407.
Cohen RV, Shikora S, Petry T, et al. The diabetes surgery summit II guidelines: a disease-based clinical recommendation. Obes Surg. 2016;26:1989–91. https://doi.org/10.1007/s11695-016-2237-6.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–256.e5. https://doi.org/10.1016/j.amjmed.2008.09.041.
Ng J, Seip R, Stone A, et al. Ethnic variation in weight loss, but not co-morbidity remission, after laparoscopic gastric banding and Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2015;11:94–100. https://doi.org/10.1016/j.soard.2014.07.013.
Kodama S, Fujihara K, Horikawa C, et al. Network meta-analysis of the relative efficacy of bariatric surgeries for diabetes remission. Obes Rev. 2018;19:1621–9. https://doi.org/10.1111/obr.12751.
Zorrilla-Nunez LF, Campbell A, Giambartolomei G, et al. The importance of the biliopancreatic limb length in gastric bypass: a systematic review. Surg Obes Relat Dis. 2019;15:43–9. https://doi.org/10.1016/j.soard.2018.10.013.
Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Obes Surg. 2017;27:2–21. https://doi.org/10.1007/s11695-016-2457-9.
Madadi F, Jawad R, Mousati I, et al. Remission of type 2 diabetes and sleeve gastrectomy in morbid obesity: a comparative systematic review and meta-analysis. Obes Surg. 2019;29:4066–76. https://doi.org/10.1007/s11695-019-04199-3.
Borgeraas H, Hofsø D, Hertel JK, et al. Comparison of the effect of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2020;21:1–11. https://doi.org/10.1111/obr.13011.
Dicker D, Golan R, Aron-Wisnewsky J, et al. Prediction of long-term diabetes remission after RYGB, sleeve gastrectomy, and adjustable gastric banding using DiaRem and advanced-DiaRem scores. Obes Surg. 2019;29:796–804. https://doi.org/10.1007/s11695-018-3583-3.
Wong RJ, Chou C, Sinha SR, et al. Ethnic disparities in the association of body mass index with the risk of hypertension and diabetes. J Community Health. 2014;39:437–45. https://doi.org/10.1007/s10900-013-9792-8.
Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology. Surg Obes Relat Dis. 2019;16:175–247. https://doi.org/10.1016/j.soard.2019.10.025.
Ramírez EM, Espinosa O, Berrones R, et al. The impact of preoperative BMI (obesity class I, II, and III) on the 12-month evolution of patients undergoing laparoscopic gastric bypass. Obes Surg. 2018;28:3095–101. https://doi.org/10.1007/s11695-018-3281-1.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This retrospective analysis was approved by the local research and ethics committees (Institutional Register 212-110-11-19) and registered at the national committees (CONBIOÉTICA-09-CEI-001-20160404).
Informed Consent
For this type of study, formal consent is not required. Every patient signed an informed consent for the surgery.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendices
Appendix 1
Appendix 2
Rights and permissions
About this article
Cite this article
Herrera, A., León, A., Rodríguez, F.M. et al. Type 2 Diabetes Mellitus Remission Models Following Laparoscopic Gastric Bypass: a 4-Model Analysis in a Latino Population. OBES SURG 31, 544–553 (2021). https://doi.org/10.1007/s11695-020-04920-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-020-04920-7